scispace - formally typeset
Y

Yoshitaka Fujii

Researcher at Nagoya City University

Publications -  306
Citations -  22300

Yoshitaka Fujii is an academic researcher from Nagoya City University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 59, co-authored 304 publications receiving 21040 citations.

Papers
More filters
Journal ArticleDOI

EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer.

TL;DR: R497KEGFR polymorphism might be associated with favorable prognosis of advanced lung cancers and correlated with chemosensitivity and no correlation existed between R497K EGFR genotype and clinico-pathological features, such as gender, smoking status, and pathological subtypes.
Journal ArticleDOI

PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.

TL;DR: A PI3K inhibitor (LY294002) inhibited the growth of an esophageal cancer cell line with a PIK3CA mutation (E545K) in vitro and was found to reduce the proliferation of the esophagal cancercell line in vitro.
Journal ArticleDOI

Expression and prognostic roles of PABPC1 in esophageal cancer: correlation with tumor progression and postoperative survival.

TL;DR: In esophageal cancer, reduced expression of PABPC1 was correlated with local tumor progression and poor prognosis after surgery, and in ESCC patients with low PAB PC1 mRNA expression had a significantly shorter postoperative survival time.
Journal ArticleDOI

Thymoma with Dissemination: Efficacy of Macroscopic Total Resection of Disseminated Nodules

TL;DR: Pursuing total resection for thymoma and disseminated nodules may be beneficial for stage IVThymoma, and the combination of preoperative steroid pulse therapy, macroscopictotal resection, and postoperative HTR may prolong the interval to relapse, but it did not lead to cure.
Journal ArticleDOI

Decreased expression of DFF45/ICAD is correlated with a poor prognosis in patients with esophageal carcinoma.

TL;DR: DNA fragmentation factor 45/inhibotor of caspase activated DNAse (ICAD) forms a complex with DFF40/CAD and inhibits its DNA cleaving function during apoptosis.